Literature DB >> 6744327

Augmentation of autologous antibody to human melanoma following acid dissociation and ultrafiltration of serum.

J M Kirkwood, D R Vlock.   

Abstract

Sera of 22 individuals were examined for immunoglobulin M (IgM) and immunoglobulin G (IgG) antibody to autologous cultured tumor cells. Reactive native IgM was detected by immune adherence in four, and IgG by Protein A hemadsorption in five, sera. Direct and absorption testing of these reactive sera against a range of normal and neoplastic cells revealed one each with specificity for a highly restricted melanoma cell surface antigen and common tumor-associated antigen of melanoma. Given this low prevalence of antibody, we then tested whether IgG antibody might be retrieved from circulating immune complexes in melanoma patients' sera. Acidification and ultrafiltration of sera from seven patients have enhanced detectable IgG binding to autologous cultured melanoma in six. Characterization of one reactive autologous antibody has detected a common antigen in eight of nine melanoma lines tested. This antibody also detected two neuroblastomas, one of two glioblastomas, one of two sarcomas, and one of two breast carcinomas. The common melanoma antigen detected in these tests may be related to the neuroectodermal, oncofetal differentiation antigens described by others with autologous or allogeneic IgM. Autologous antitumor antibody in circulating immune complexes may provide a source of antibody for serodiagnostic and therapeutic applications relevant to treatment modalities, such as plasmapheresis and plasma perfusion over Protein A in melanoma and other cancers.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6744327

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Serial studies of autologous antibody reactivity to melanoma. Relationship to clinical course and circulating immune complexes.

Authors:  D R Vlock; J M Kirkwood
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

2.  Recovery of a cell surface fetal antigen from circulating immune complexes of melanoma patients.

Authors:  J H Wong; B Aguero; R K Gupta; D L Morton
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

3.  Human IgG and IgM monoclonal antibodies against autologous melanoma produced by Epstein-Barr-virus-transformed B lymphocytes.

Authors:  J M Kirkwood; J E Robinson
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Serial studies of autologous antibody reactivity to squamous cell carcinoma of the head and neck.

Authors:  D R Vlock; B Arnold; J Humpierres; D R Schwartz; S R Baker; C J Krause; N Swanson; T E Carey
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

5.  Phase II study of vaccinia melanoma cell lysates (VMCL) as adjuvant to surgical treatment of stage II melanoma. II. Effects on cell mediated cytotoxicity and leucocyte dependent antibody activity: immunological effects of VMCL in melanoma patients.

Authors:  P Hersey; A Edwards; G D'Alessandro; M MacDonald
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

6.  Prognostic role of antibody reactivity to melanoma.

Authors:  D R Vlock; R DerSimonian; J M Kirkwood
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

7.  Immunodiagnosis of human malignancy.

Authors:  H F Seigler
Journal:  Ann Surg       Date:  1985-04       Impact factor: 12.969

8.  Isolation and partial characterization of melanoma-associated antigens identified by autologous antibody.

Authors:  D R Vlock; D Scalise; N Meglin; J M Kirkwood; B Ballou
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.